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ABSTRACT
Escherichia coli O157:H7 is a virulent foodborne pathogen that causes severe human illness and inhabits the intestinal
tract of food animals. Colicins are antimicrobial proteins produced by E. coli strains that inhibit or kill other E. coli. In the
present study, the efficacy of three pore-forming colicins (E1, N, and A) were quantified in vitro against E. coli O157:H7
strains 86-24 and 933. Colicins E1 and N reduced the growth of E. coli O157:H7 strains, but the efficacy of each colicin
varied among strains. Colicin E1 was more effective against both strains of E. coli O157:H7 than colicins A and N and
reduced (P , 0.05) populations of E. coli O157:H7 at concentrations ,0.1 mg/ml. These potent antimicrobial proteins may
potentially provide an effective and environmentally sound preharvest strategy to reduce E. coli O157:H7 in food animals.
Enterohemorrhagic Escherichia coli (EHEC) such as E.
coli O157:H7 annually cause 93,000 illnesses at a cost to
the U.S. economy of approximately $1 billion (7). Many
of these illnesses have been linked to consumption of foods
derived from or contaminated by animal products (4, 21).
Because pathogenic bacteria are commonly found as mem-
bers of the gastrointestinal population of food animals (19,
24, 25), they can be introduced into the abattoir within the
feces of cattle or attached to their hide (5, 6, 8, 26).
A variety of postslaughter intervention strategies have
been implemented in slaughter plants over the past 10 years
(e.g., steam treatment, hair removal) that significantly re-
duce pathogen levels on carcasses (6, 8). However, in spite
of these innovative interventions, foodborne illnesses
linked to meat products still occur far too frequently. Thus,
strategies to reduce foodborne pathogens in animals prior
to slaughter holds significant promise in reducing human
illness (12).
Colicins are antimicrobial proteins produced by certain
E. coli strains that kill or inhibit the growth of other E. coli
strains (15, 16, 28). Colicins have been shown to be effec-
tive against E. coli O157:H7 strains (13, 23, 27); however,
studies examining the efficacy of different colicins have
typically yielded qualitative rather than quantitative results.
In this study, we quantitatively compared the efficacy of
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three purified colicins (A, E1, and N) against E. coli O157:
H7 strains.
MATERIALS AND METHODS
Colicin production and purification. Each colicin was pro-
duced from a specific colicin-producing E. coli K-12 strain
(NC50129-01 containing plasmid pColA-CA31, NC50132-01
containing plasmid pColE1-K53, and NC50145-01 containing
plasmid pColN-284) obtained from the National Collection of
Type Cultures (Public Health Laboratory Service, London, UK).
Cultures were inoculated into Luria-Bertani (LB) broth to an ini-
tial optical density at 600 nm (OD600) of approximately 0.1 and
incubated in a shaker at 378C. When the cultures reached OD600
5 0.9, colicin production was induced by the addition of 0.2 U
of mitomycin C per ml of culture (Sigma Chemicals, St. Louis,
Mo.). The cell-free supernatant was obtained by centrifugation 5.5
h later and concentrated by ultrafiltration in a stir-cell apparatus
(Amicon, Millipore, Bedford, Mass.) across a regenerated cellu-
lose membrane with a 30-kDa cut-off (Millipore). The concen-
trated sample was then desalted against 10 mM Tris-Cl, pH 8, and
purified by ion exchange chromatography. The desalted samples
were applied to a column containing Q Sepharose (Amersham
Biosciences, Piscataway N.J.), equilibrated with 10 mM Tris-Cl,
pH 8.0 (equilibration buffer), and exhaustively washed with the
equilibration buffer. The bound protein was eluted with a contin-
uous NaCl gradient on an AKTAprime chromatography system
(Amersham Bioscience). The fractions containing the highest con-
centrations of colicin, determined by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis followed by Coomasie blue
staining, were pooled and concentrated by ultrafiltration. The pro-
tein concentrations of these samples were determined in each
pooled sample (20), and percent colicin was determined by den-
sitometry with the use of a 16-bit megapixel charge-coupled de-
vice camera (FluorChem 8800, Alpha Innotech, San Leandro, Ca-
lif.) and FluorChem IS800 software (Alpha Innotech).
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FIGURE 1. Effect of colicins A, N, and E1 (4.1 mg/ml for each
individual colicin) on increase in optical density (600 nm) of E.
coli O57:H7 strains 933 (a) and 86-24 (b). V, control; v, colicin
A–treated; n, colicin E1–treated; and m, colicin N–treated cul-
tures.
Bacterial strains and culture conditions. E. coli O157:H7
strains 933 (ATCC 43895) and 86-24 were obtained from the Food
and Feed Safety Research Unit culture collection (U.S. Depart-
ment of Agriculture/Agricultural Research Service, College Sta-
tion, Tex.); both strains were originally isolated from human hem-
orrhagic colitis outbreaks. E. coli O157:H7 strain 933 was natu-
rally resistant to 25 mg/ml novobiocin and were made resistant to
20 mg/ml nalidixic acid by repeated transfer and selection. E. coli
O157:H7 86-24 was made resistant to streptomycin (100 mg/ml)
by repeated transfer and selection. Differences in growth rates and
antibiotic resistance profiles (other than for specifically selected
and closely related antibiotics) were not detected between these
antibiotic-resistant strains and wild-type parental strains (data not
shown).
Escherichia coli O157:H7 strains 933 (ATCC 43895) and 86-
24 were anaerobically (90% N2, 5% H2, 5% CO2 atmosphere)
incubated at 398C in anoxic tryptic soy broth (Difco Laboratories,
Detroit, Mich.) to ensure colicin activity under anaerobic condi-
tions similar to those within the gastrointestinal tract. Growth rates
(n 5 2) were estimated via measurement of absorbance changes
with a Spectronic 20D spectrophotometer (600 nm, Thermo Spec-
tronic Inc., Madison, Wis.); growth rate was calculated with the
formula (ln OD2 2 ln OD1)/DT. Final optical densities after 24 h
of incubation were measured with a Gilford 2600 spectrophotom-
eter (600 nm, 1-cm cuvette). Cultures with optical densities great-
er than 0.7 OD units were appropriately diluted in 0.9% NaCl.
Quantitative bacterial enumeration. Samples were taken
from incubations at 6 and 24 h to determine the effect of colicins
on populations of E. coli O157:H7. Samples were serially diluted
(in 10-fold increments) in phosphate-buffered saline (pH 7.0) and
subsequently plated on MacConkey’s agar (supplemented with 25
mg/ml novobiocin and 20 mg/ml nalidixic acid for E. coli O157:
H7 strain 933 or with 100 mg/ml streptomycin for E. coli O157:
H7 strain 86-24) and incubated at 378C overnight for direct count-
ing (CFU per milliliter).
Colicin addition. To initially evaluate the effectiveness of
these colicins against E. coli O157:H7 strains, cultures were in-
oculated into tryptic soy broth tubes containing equivalent con-
centrations (4.1 mg/ml) of each of the individual colicins tested
(A, E1, and N). To determine the effective range of doses for use
in more complex mixed culture and in vivo studies, freshly in-
oculated tryptic soy broth was added (5 ml) to culture tubes con-
taining concentrations (0 to 40.8 mg of each colicin per ml) of
colicin A, colicin E1, and colicin N. The total volume of each
colicin addition, including the 0 mg/ml colicin control, was 175
ml; the volume of the colicin dose was made constant by the
addition of sterile, anoxic 10 mM Tris, pH 8. To determine the
lowest effective dose of colicin E1 against both E. coli O157:H7
strains, cultures were grown in the presence of 0, 0.016, 0.032,
0.064, 0.128, 0.255, 0.51, 1.02, 2.04, 4.1, 7.7, 15.4, 28.8, and 40.8
mg of colicin E1 per ml.
Statistical analysis. Experiments were performed in dupli-
cate, and the values presented are means. Students’ t test was used
to determine significance of differences between means.
Chemicals. Unless specifically mentioned, all chemicals
were obtained from Sigma Chemical Company.
RESULTS
Effect of colicins on E. coli O157:H7. E. coli O157:
H7 grew rapidly in tryptic soy broth, but the addition of
colicins affected growth (Fig. 1a and 1b). Colicin E1 sig-
nificantly (P , 0.05) reduced growth of both E. coli O157:
H7 strains 933 and 86-24 (Fig. 1a and 1b). Colicin N did
not affect the growth rate of E. coli O157:H7 strain 933
(Fig. 1a) but did reduce the OD or growth rate of E. coli
O157:H7 strain 86-24 (Fig. 1b). Colicin A did not affect
the OD of either strain of E. coli O157:H7. Colicin E1
significantly (P , 0.05) reduced the specific growth rate of
both strains of E. coli O157:H7 examined at low concen-
trations (Fig. 2a and 2b). Colicin N was nearly as effective
as E1 against strain 86-24 but was not (P . 0.10) effective
against strain 933.
Regardless of the colicin dose used, all E. coli O157:
H7 cultures eventually grew overnight; therefore, final (24
h) optical densities were not significantly reduced in either
strain by any of the colicins (data not shown).
Bacterial populations of both E. coli O157:H7 strains
were unaffected by colicin A (Fig. 3a and 3b). Treatment
with colicin E1 significantly (P , 0.05) reduced E. coli
O157:H7 populations by at least 4 log units for both strains
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FIGURE 2. Effect of various concentrations of colicins A, N, and
E1 on the maximal specific growth rates (h21) of E. coli O57:H7
strains 933 (a) and 86-24 (b). n, colicin A–treated; V, colicin
E1–treated; and v, colicin N–treated cultures.
FIGURE 3. Effect of concentrations of colicins A, N, and E1 on
bacterial populations (CFU/ml) of E. coli O57:H7 strains 933 (a)
and 86-24 (b) after 6 h of incubation. n, colicin A–treated; V,
colicin E1–treated; and v, colicin N–treated cultures.
tested, whereas colicin N significantly (P , 0.05) reduced
populations only for E. coli O157:H7 strain 86-24 (Fig. 3b).
Because of the sensitivity of both strains of E. coli O157:
H7 to colicin E1, we examined the efficacy of very low
doses against these strains. Colicin E1 reduced (P , 0.05)
the specific growth rate of both strains of E. coli O157:H7
at concentrations below 0.1 mg/ml (Fig. 4). In a negative
control, Salmonella Typhimurium culture growth rates, fi-
nal OD, and populations were not affected by any colicin
treatment (data not shown).
DISCUSSION
The primary route of infection by E. coli O157:H7 in
humans is consumption of improperly cooked or handled
ground beef (31), although serious waterborne outbreaks
have occurred (3, 32). To reduce exposure of humans to
these pathogens, it is therefore logical to conceptualize the
use of antibiotics to reduce carriage of foodborne pathogens
in the gut (9). However this strategy is not likely to be
acceptable to the public because of widespread concerns
over antibiotic resistance (1, 33–36). Therefore alternative
antimicrobial strategies that generally or specifically target
foodborne pathogens must be developed.
Colicins are small proteins (29 to 75 kDa in size) pro-
duced by certain E. coli strains that exhibit antimicrobial
activity (15, 16, 28) by binding to specific outer membrane
receptors of sensitive bacteria, translocating across the outer
membrane spanning the periplasm, and inserting into the
inner membrane (16–18). Following insertion into the inner
membrane, the pore-forming colicins, such as colicin E1,
A, and N, create a voltage-dependent pore that allows ions
to flow out of the cytoplasm, destroying the electrochemical
gradients and the protonmotive force (10, 11, 14). Cellular
death results from a loss of K1, as well as a depletion of
intracellular ATP and other phosphorylated intermediates
(16, 30).
The concept of using colicins as an intervention strat-
egy to kill foodborne pathogens is not new (23); however,
this is the first study to quantitatively evaluate the efficacy
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FIGURE 4. Effect of lowest colicin E1 concentrations (mg/ml) on
the maximal specific growth rate (h21) of E. coli O157:H7 strains.
Error bars indicate standard deviations.
of various colicins against E. coli O157:H7. In previous
studies, colicin activities against several E. coli O157:H7
strains were qualitatively determined in agar overlays (23,
27). This method of evaluation of colicin activity has been
used primarily because of the difficulty in obtaining suffi-
cient quantities of purified colicin proteins. Because of
costs associated with the production and purification of
these colicins from their native producers, it was unlikely
that a quantitative determination of their efficacy would
ever be needed for commercial application. However, recent
recombinant protein expression work in our laboratories has
created a need for this information to be able to compare
native versus recombinantly expressed colicins (29).
In this study, colicin E1 was the most effective colicin.
This result agrees with previous data indicating that colicin
E1 displayed antimicrobial activity against several EHEC
strains, not just O157:H7 (13). Other E-type colicins were
found to be suitable candidates as ‘‘biopreservatives’’
against E. coli O157:H7 (22). However, other studies have
indicated that the sensitivity of E. coli O157:H7 strains to
any single colicin can be highly variable (22, 23, 27). For
example, only 1 of 18 colicins examined inhibited all 540
E. coli O157:H7 strains screened (27). Because some E.
coli O157:H7 strains are colicinogenic and produce specific
concomitant immunity proteins (22), they can be resistant
to certain colicins or even a broad category of colicins (2).
Therefore, simultaneous administration of a mixture of sev-
eral categories of colicins should be considered as a treat-
ment concept to reduce E. coli O157:H7 (and other EHEC)
in the gastrointestinal tract of food animals. However, for
colicins to be a viable anti–E. coli O157:H7 intervention
strategy, the proteins must be protected from gastric and
intestinal degradation. Technologies exist to target release
of compounds in specific locations throughout the gastro-
intestinal tract; therefore, these techniques should be con-
sidered for use in further development and application stud-
ies.
In this study, we found that some highly active colicins
can be used as a potential method of reducing E. coli O157:
H7 populations. It is envisioned that colicins could be pro-
tected from gastric, intestinal, or both kinds of degradation
to serve as an intervention strategy to reduce foodborne
pathogenic bacteria in the live animal. Further research is
required to elucidate the optimal colicin dosing strategies
required to control EHEC carriage in food animals.
REFERENCES
1. Alliance for the Prudent Use of Antibiotics. 1999. Facts about an-
tibiotics in animals and their impact on resistance. APUA. Available
at: http://www.tufts.edu/med/apua/Ecology/faair.html. Accessed 23
October 2002.
2. Alonso, G., G. Vilchez, and R. L. Vidal. 2000. How bacteria protect
themselves against channel-forming colicins. Int. Microbiol. 3:81–
88.
3. Anonymous. 2000. Waterborne outbreak of gastroenteritis associated
with a contaminated municipal water supply, Walkerton, Ontario,
May–June 2000. Can. Commun. Dis. Rep. 26:170–173.
4. Armstrong, G. L., J. Hollingsworth, and J. G. Morris. 1996. Emerg-
ing foodborne pathogens: Escherichia coli O157:H7 as a model of
entry into the food supply of the developed world. Epidemiol. Rev.
18:29–51.
5. Aslam, M., F. Nattress, G. Greer, C. Yost, C. Gill, and L. McMullen.
2003. Origin of contamination and genetic diversity of Escherichia
coli in beef cattle. Appl. Environ. Microbiol. 69:2794–2799.
6. Barkocy-Gallagher, G. A., T. M. Arthur, M. Rivera-Betancourt, X.
Nou, S. D. Shackelford, T. L. Wheeler, and M. Koohmaraie. 2003.
Seasonal prevalence of shiga toxin–producing Escherichia coli, in-
cluding O157:H7 and non-O157 serotypes, and Salmonella in com-
mercial beef processing plants. J. Food Prot. 66:1978–1986.
7. Economic Research Service/U.S. Department of Agriculture. 2001.
ERS estimates foodborne disease costs at $6.9 billion per year. ERS/
USDA. Available at: http://www.ers.usda.gov/Emphases/SafeFood/
features.htm. Accessed 28 April 2004.
8. Elder, R. O., J. E. Keen, G. R. Siragusa, G. A. Barkocy-Gallagher,
M. Koohmaraie, and W. W. Lagreid. 2000. Correlation of entero-
hemorrhagic Escherichia coli O157 prevalence in feces, hides, and
carcasses of beef cattle during processing. Proc. Natl. Acad. Sci.
USA 97:2999–3003.
9. Elder, R. O., J. E. Keen, T. E. Wittum, T. R. Callaway, T. S. Edring-
ton, R. C. Anderson, and D. J. Nisbet. 2002. Intervention to reduce
fecal shedding of enterohemorrhagic Escherichia coli O157:H7 in
naturally infected cattle using neomycin sulfate. J. Anim. Sci.
80(Suppl. 1):15. (Abstract.)
10. Gouaux, E. 1997. The long and short of colicin action: the molecular
basis of the biological activity of channel-forming colicins. Structure
5:313–317.
11. Guihard, G., H. Benedetti, M. Besnard, and L. Letellier. 1993. Phos-
phate efflux through the channels formed by colicins and phage T5
in Escherichia coli cells is responsible for the fall in cytoplasmic
ATP. J. Biol. Chem. 268:17,775–17,780.
12. Hynes, N. A., and I. K. Wachsmuth. 2000. Escherichia coli O157:
H7 risk assessment in ground beef: a public health tool, p. 46. Abstr.
Proc. 4th Int. Symp. on Shiga Toxin–Producing Escherichia coli In-
fections, Kyoto, Japan. VTEC Committee, Kyoto, Japan.
13. Jordi, B. J. A. M., K. Boutaga, C. M. E. Van Heeswijk, F. Van
Knapen, and L. J. A. Lipman. 2001. Sensitivity of shiga toxin–pro-
ducing Escherichia coli (STEC) strains for colicins under different
experimental conditions. FEMS Microbiol. Lett. 204:329–344.
14. Klenker, P., S. L. Slatin, and A. Finkelstein. 2002. Colicin channels
have a shockingly high proton permeability. Biophys. J. 82(1 Part
2):555a.
J. Food Prot., Vol. 67, No. 11 EFFECT OF COLICINS ON E. COLI O157:H7 2607
15. Konisky, J. 1982. Colicins and other bacteriocins with established
modes of action. Ann. Rev. Microbiol. 36:125–144.
16. Lakey, J. H., and S. L. Slatin. 2001. Pore-forming colicins and their
relatives, p. 131–161. In F. G. Van Der Goot (ed.), Pore-forming
toxins. Springer-Verlag GmbH & Co. KG, Berlin.
17. Lazdunski, C. J., E. Bouveret, A. Rigal, L. Journet, R. Lloubes, and
H. Benedetti. 1998. Colicin import into Escherichia coli cells. J.
Bacteriol. 180:4993–5002.
18. Lazdunski, C. J., E. Bouveret, A. Rigal, L. Journet, R. Lloubes, and
H. Benedetti. 2000. Colicin import into Escherichia coli cells re-
quires the proximity of the inner and outer membranes and other
factors. Int. J. Med. Microbiol. 290:337–344.
19. LeJeune, J. T., T. E. Besser, D. H. Rice, J. L. Berg, R. P. Stillborn,
and D. D. Hancock. 2004. Longitudinal study of fecal shedding of
Escherichia coli O157:H7 in feedlot cattle: predominance and per-
sistence of specific clonal types despite massive cattle population
turnover. Appl. Environ. Microbiol. 70:377–385.
20. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951.
Protein measurement with the folin phenol reagent. J. Biol. Chem.
193:265–275.
21. Mead, P. S., L. Slutsker, V. Dietz, L. F. McCraig, J. S. Bresee, C.
Shapiro, P. M. Griffin, and R. V. Tauxe. 1999. Food-related illness
and death in the United States. Emerg. Infect. Dis. 5:607–625.
22. Murinda, S. E., S. M. Liu, R. F. Roberts, and R. A. Wilson. 1998.
Colicinogeny among Escherichia coli serotypes, including O157:H7,
representing four closely related diarrheagenic clones. J. Food Prot.
61:1431–1438.
23. Murinda, S. E., R. F. Roberts, and R. A. Wilson. 1996. Evaluation
of colicins for inhibitory activity against diarrheagenic Escherichia
coli strains, including serotype O157:H7. Appl. Environ. Microbiol.
62:3192–3202.
24. Naylor, S. W., J. C. Low, T. E. Besser, A. Mahajan, G. J. Gunn, M.
C. Pearce, I. J. McKendrick, D. G. E. Smith, and D. L. Gally. 2003.
Lymphoid follicle-dense mucosa at the terminal rectum is the prin-
cipal site of colonization of enterohaemorrhagic Escherichia coli
O157:H7 in the bovine host. Infect. Immun. 71:1505–1512.
25. Omisakin, F., M. MacRae, I. D. Ogden, and N. J. C. Strachan. 2003.
Concentration and prevalence of Escherichia coli O157:H7 in cattle
feces at slaughter. Appl. Environ. Microbiol. 69:2444–2447.
26. Reid, C. A., A. Small, S. M. Avery, and S. Buncic. 2002. Presence
of foodborne pathogens on cattle hides. Food Control 13:411–415.
27. Schamberger, G. P., and F. Diez-Gonzalez. 2002. Selection of re-
cently isolated colicinogenic Escherichia coli strains inhibitory to
Escherichia coli O157:H7. J. Food Prot. 65:1381–1387.
28. Smarda, J., and D. Smajs. 1998. Colicins—exocellular lethal proteins
of Escherichia coli. Folia Microbiol. 43:563–582.
29. Stahl, C. H. Unpublished data.
30. Stroud, R. M., K. Reiling, M. Wiener, and D. Freymann. 1998. Ion
channel-forming colicins. Curr. Opin. Struct. Biol. 8:525–533.
31. U.S. Department of Agriculture/Animal and Plant Health Inspection
Service. 1997. An update: Escherichia coli O157:H7 in humans and
cattle. Center for Epidemiology and Animal Health, Fort Collins,
Colo.
32. U.S. Department of Health and Human Services. 1999. Outbreak of
Escherichia coli 0157:H7 and Campylobacter among attendees of
the Washington county fair—New York 1999. Morb. Mortal. Wkly.
Rep. 48:803–804.
33. U.S. Food and Drug Administration. 1999. Consideration of the hu-
man health impact of the microbial effects of antimicrobial new an-
imal drugs intended for use in food producing animals. Fed. Regist.
64:70,715–70,716.
34. U.S. Food and Drug Administration. 2002. Evaluating the safety of
antimicrobial new animal drugs with regard to their microbiological
effects on bacteria of human health concern. Docket no. 98D-1146.
Fed. Regist. 67:58,058–58,060.
35. Witte, W. 1999. Antibiotic use in animal husbandry and resistance
development in human infections. Alliance Prudent Use Antibiot. 16:
1–7.
36. World Health Organization (WHO). 2000. Global principles for the
containment of antimicrobial resistance in animals intended for food.
WHO, Geneva, Switzerland.
